Comparing two ways to prevent CMV infection after kidney transplant
Part of Immune system & allergy, Infections, Kidney & urinary clinical trials.
This study compares two ways to prevent cytomegalovirus (CMV) infection after a kidney transplant in people who are at higher risk. One group gets a medicine called tacrolimus plus an MTOR inhibitor (sirolimus or everolimus) and only takes an antiviral if CMV is detected early. The other group gets tacrolimus plus mycophenolic acid and takes an antiviral medicine every day as a precaution. The goal is to find out which approach works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Before the transplant, a blood test shows you have been exposed to cytomegalovirus (CMV) in the past – this is very common.
- You will receive a medicine called thymoglobulin right after the transplant to help keep your immune system from rejecting the new kidney.
- You do not have HIV.
- You will not receive basiliximab (another induction medicine) as part of this transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests whether switching one of your anti-rejection medicines to a drug called everolimus can help clear a CMV infection. The goal is to see if this approach works better than standard care.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.